Geovax Labs Inc
GOVX
Company Profile
Business description
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.
Contact
1900 Lake Park Drive
Suite 380
SmyrnaGA30080
USAT: +1 678 384-7220
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
17
Stocks News & Analysis
stocks
Ask the analyst: Are IDP Education's woes temporary?
The global education services provider has gone from stock market darling to one of the ASX's weakest performers. What gives?
stocks
Is it time to buy the Magnificent Seven?
After the recent selloff, the bull market’s most in-demand stocks look much cheaper.
stocks
Chart of the week: Did ASX companies underwhelm or impress during earnings season?
The Chart of the Week looks at how our Fair Values changes for Australian companies during earnings season.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,966.60 | 136.80 | -1.69% |
| CAC 40 | 7,988.96 | 47.05 | 0.59% |
| DAX 40 | 22,676.41 | 347.64 | 1.56% |
| Dow JONES (US) | 41,350.93 | 82.55 | -0.20% |
| FTSE 100 | 8,521.47 | 25.48 | 0.30% |
| HKSE | 23,251.07 | 531.07 | -2.23% |
| NASDAQ | 17,648.45 | 212.35 | 1.22% |
| Nikkei 225 | 36,835.72 | 42.61 | 0.12% |
| NZX 50 Index | 12,209.05 | 201.92 | -1.63% |
| S&P 500 | 5,599.30 | 27.23 | 0.49% |
| S&P/ASX 200 | 7,749.10 | 141.00 | -1.79% |
| SSE Composite Index | 3,344.60 | 27.32 | -0.81% |